Taysha Gene Therapies, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Financial statements are unaudited. Taysha is a clinical-stage gene therapy company and reported no product sales; its revenue came from research and development services under its Astellas agreement.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / prior balance |
|---|---|---|
| Revenue | $4.7 million | $0 |
| Research and development expense | $12.5 million | $38.2 million |
| General and administrative expense | $8.8 million | $11.5 million |
| Total operating expenses | $21.3 million | $49.7 million |
| Net loss | $17.6 million | $50.3 million |
| Net loss per share, basic and diluted | $0.28 | $1.32 |
| Net cash used in operating activities | $20.2 million | $40.9 million |
| Net cash used in investing activities | $3.9 million | $11.4 million |
| Cash and cash equivalents, March 31 | $63.4 million | $87.9 million at Dec. 31, 2022 |
| Restricted cash, March 31 | $2.6 million | $2.6 million at Dec. 31, 2022 |
| Term loan, net, March 31 | $38.2 million | $38.0 million at Dec. 31, 2022 |
| Accumulated deficit, March 31 | $419.1 million | $401.4 million at Dec. 31, 2022 |
The filing does not present a meaningful product gross margin; revenue reflects Astellas-funded Rett research and development activities. No product-sales revenue has been generated. Total liabilities were $116.5 million, including $21.4 million of operating lease liabilities and $38.2 million of net term debt. The term loan has interest-only payments through August 2024, followed by principal and interest installments, with maturity in August 2026. The company reported compliance with loan covenants.
Changes versus the comparable period
- Revenue rose from zero to $4.7 million as Taysha performed Rett research and development activities under the Astellas agreement; deferred revenue declined to $28.9 million.
- Operating expenses fell $28.4 million year over year. R&D expense decreased $25.7 million, primarily reflecting lower headcount, manufacturing and raw-material purchases, and nonclinical studies. G&A expense declined $2.7 million, mainly due to lower compensation and professional fees.
- Net loss narrowed by $32.7 million, while operating cash use declined by $20.8 million. Investing cash use also fell, including because Q1 2023 capital spending related to closing out the in-house manufacturing facility project.
- Interest expense increased to $1.4 million from $0.7 million, primarily due to higher term-loan interest expense.
Outlook, management commentary, and risks
- Liquidity and going concern: Management said existing cash and cash equivalents were expected to fund operations into the first quarter of 2024. The filing states funding is insufficient for currently planned research and discovery programs beyond one year from filing and that substantial doubt exists about the company’s ability to continue as a going concern. Taysha expects to need additional capital; availability and terms are uncertain.
- Spending and commitments: Management anticipated lower 2023 spending than 2022 due to pipeline prioritization, while also expecting R&D costs—particularly for Rett clinical trials—to increase as development advances. The filing identifies $34.6 million of total lease payments under noncancelable leases and approximately $10.4 million of cancellable purchase obligations to clinical vendors and others.
- Pipeline: Taysha’s focus is TSHA-120 for giant axonal neuropathy (GAN) and TSHA-102 for Rett syndrome; substantially all other R&D programs were paused or deprioritized. FDA feedback on TSHA-120 supported MFM32 as a relevant endpoint but recommended additional patients in a double-blind, placebo-controlled design to support a BLA. FDA review of the submitted manufacturing comparability information remained pending. The company planned a further FDA meeting on GAN and expected to dose the first adult Rett patient and report initial available data in the first half of 2023; these were forward-looking plans, not results reported in this filing.
- Astellas agreement: Astellas holds options to license GAN and Rett programs. The $36.1 million transaction price is being recognized as performance obligations are satisfied; Rett R&D revenue was $4.7 million in Q1. If an option is exercised, financial terms would be negotiated under the agreement, and the $20 million upfront payment may be offset against specified future payments.
- Restructuring: Further headcount reductions in late 2022 and Q1 2023 resulted in $2.7 million of severance costs; $3.0 million of severance remained accrued at March 31, with payments expected to be completed by March 2024.
- Subsequent events: Nasdaq notified Taysha on April 25, 2023 that its bid price had been below $1.00 for 30 consecutive business days, giving it until October 23, 2023 to regain compliance. In April, Taysha also completed a private placement with SSI affiliates for $0.5 million gross proceeds, issuing 705,218 shares and warrants for 525,000 shares subject to clinical and regulatory milestones.
- The company reported no material legal proceedings and no material changes to its previously disclosed risk factors other than the Nasdaq bid-price deficiency. Management stated disclosure controls were effective as of March 31, 2023.
Important facts for investors to verify
- Cash runway and financing needs, given the stated going-concern substantial doubt and anticipated need for additional capital.
- Clinical progress and regulatory feedback for TSHA-120 and TSHA-102, including the FDA’s study-design and safety-database expectations and outstanding manufacturing comparability review.
- Nasdaq bid-price compliance status and any resulting effects on listing, liquidity, or access to financing.
- Future cash burn, severance payments, lease obligations, and the extent to which the Astellas deferred revenue is recognized or its options are exercised.
- Potential dilution from future equity financing, employee awards, and the SSI warrants.